Clinical Trial Update: A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 dose-ranging trial of PD 0200390 in elderly subjects with primary insomnia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• PD 0200390

Snippet

Sponsor: Pfizer | Conditions: Insomnia | Phase 2 | Status: WITHDRAWN